Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer
Introduction
Androgen deprivation therapy (ADT) is the main treatment for patients diagnosed with metastatic or relapsed prostate cancer [1]. After an initial response, most patients will eventually progress, leading to the castration-resistant prostate cancer (CRPC) [2]. Docetaxel chemotherapy has been widely used for patients with metastatic CRPC. Androgen signalling remains the main oncogenic driver pathway in CRPC [3] and new strategies to improve its inhibition have successfully developed. Abiraterone acetate, an oral CYP17 inhibitor, improves overall survival (OS) in both chemotherapy-naïve and chemotherapy-pretreated metastatic CRPC (mCRPC) patients [4], [5], [6]. An OS benefit in the same patient profile was demonstrated with enzalutamide, a next-generation androgen receptor (AR) inhibitor [7], [8]. Cabazitaxel, a new taxane compound, improved OS in chemotherapy-pretreated patients [9]. Sipuleucel-T improves OS, mostly in chemotherapy-naïve patients [10], and radium-223 was shown to improve outcome in the pre- and post-docetaxel setting [11]. Finally, the bone-targeting agent denosumab demonstrated a delay in the onset of skeletal-related events in men with symptomatic bone mCRPC [12].
Since not all CRPC patients benefit from these treatments due to primary resistance, there is an urgent need to identify predictive biomarkers of sensitivity to assist decision-making in patients with CRPC and avoid useless side-effects and costs from a poorly performing drug. Intense translational research efforts are ongoing in this direction. We aimed to investigate ready-to-use clinical predictors of improved outcome, notably of PFS, in CRPC patients treated with AR axis targeted drugs.
Section snippets
Patient selection
In this retrospective study we pooled the clinical databases from two comprehensive cancer centres, the Gustave Roussy Institute (IGR) and the Institut Jean Godinot, Reims, France. Patients treated with AR axis targeted drugs for histologically confirmed prostate cancer in the metastatic castration-resistance phase were included. Patients for whom the exact time of ADT initiation and castration resistance was not available were excluded. CRPC was defined as biochemical or radiological disease
Patients and disease characteristics
The study cohort included 173 patients. Data collection was between January 2012 and December 2014 (data of last follow-up). Patient and disease characteristics at diagnosis and at treatment start with the AR axis targeted drug in the CRPC setting are summarised in Table 1. Median TTCRPC was 17.8 months (25th percentile: 11.3 months; 75th percentile: 32 months). Most patients received docetaxel chemotherapy with a median time to progression of 6.7 months (range: 1–17 months). The median pretreatment
Discussion
No strong clinical data exist to provide guidance for the optimal administration of drugs in the CRPC setting. Given the number of existing options in the AR axis targeted drugs, we aimed to identify a reliable cross-cutting predictive factor of efficacy of these therapies. We show that a short duration of response to ADT (TTCRPC < 12 months) is predictive of shorter PFS and lower efficacy (PSA response) in patients treated with next-generation AR axis targeted drugs. Given the heterogeneity of
Conflict of interest statement
Yohann Loriot: honoraria/consultantship from Astellas, Janssen, Sanofi-Aventis. Karim Fizazi: honoraria/consultantship from Astellas, Janssen. Christophe Massard: honoraria/consultantship from Janssen. The other authors do not have any conflict of interest to declare.
Acknowledgements
No specific funding source or writing assistance was used for this article.
References (32)
- et al.
Prostate cancer: ESMO consensus conference guidelines 2012
Ann Oncol
(2013) - et al.
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
J Urol
(2002) - et al.
Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel
Lancet Oncol
(2012) - et al.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Lancet Oncol
(2015) - et al.
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Lancet
(2010) - et al.
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Lancet
(2011) - et al.
New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1)
Eur J Cancer
(2009) - et al.
Secondary hormonal therapy in men with castration-resistant prostate cancer
Clin Genitourin Cancer
(2011) - et al.
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
Eur Urol
(2011) - et al.
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
Cancer Cell
(2011)
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth
Cancer Cell
Visceral disease in castration-resistant prostate cancer
Eur Urol
Targeting continued androgen receptor signaling in prostate cancer
Clin Cancer Res
Abiraterone and increased survival in metastatic prostate cancer
N Eng J Med
Increased survival with enzalutamide in prostate cancer after chemotherapy
N Engl J Med
Enzalutamide in metastatic prostate cancer before chemotherapy
N Engl J Med
Cited by (70)
Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide
2023, Clinical Genitourinary CancerFrench AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance
2022, Progres en UrologieCitation Excerpt :En revanche, en 1re ou 2e ligne de chimiothérapie, il n’y a pas de différence en termes de survie globale entre la forme 20 ou 25 mg/m2 [115,116]. Parmi les critères qui vont orienter le choix entre une HTNG et une chimiothérapie, il faut considérer un certain nombre de facteurs comme le statut de performance et l’âge, la présence de métastases viscérales, le caractère symptomatique ou pas des métastases, le caractère très indifférencié neuro-endocrine de la tumeur (selon les critères d’Aparicio), le temps entre l’initiation de la SAd et la résistance à la castration avec une limite approximative de 12 mois [118,119]. Ainsi, chez les patients éligibles présentant une différenciation neuro-endocrine, ou en présence d’un échappement rapide après hormonothérapie initiale (inférieur à un an), une chimiothérapie sera privilégiée.
Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer
2020, Urologic Oncology: Seminars and Original InvestigationsPrognostic significance of antihypertensive agents in men with castration-resistant prostate cancer
2019, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :Thus, several therapeutic options are available for CRPC, highlighting the need to identify biomarkers that enable selection of a suitable therapy for each patient. Several biomarkers have been suggested to predict a positive response to ARAT agents and taxane chemotherapies; these include the duration of response to primary ADT [5,6]; expression of the androgen receptor (AR) splice variant; and aberrations in the AR gene, DNA repair genes, and tumor-suppressor genes [7,8]. Hypertension (HTN) is a known risk factor for prostate cancer, albeit modest [9].
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care
2024, Prostate Cancer and Prostatic Diseases